Abstract
The anti-inflammatory, analgesic and antipyretic properties of the new non-steroidal anti-inflammatory agent, meloxicam, were investigated in a variety of animal models and compared with the properties of piroxicam, diclofenac, indomethacin and several other NSAIDs.
With respect to the total effect of a single oral dose, the anti-exudative effect of meloxicam on carrageenaninduced oedema in the rat exceeded that of all the NSAIDs included in the comparison. Additionally, meloxicam showed the greatest potency of all the compounds examined with respect to adjuvant-induced arthritis in the rat, the granuloma pouch model and the cotton pellet test in the rat. Unlike indomethacin, in the carrageenan pleurisy model in the rat, meloxicam caused both a dose-dependent reduction in exudate volume and also inhibition of leucocyte migration.
Meloxicam showed a strong and lasting effect on inflammatory pain in the rat. Like other NSAIDs, but unlike dipyrone, meloxicam had no effect in the hot plate and tail clamp tests, which are used to identify weak central analgesic effects. Unlike dipyrone and like indomethacin, meloxicam had no effect in a model of visceral distention pain.
In common with other NSAIDs, meloxicam had no influence on the body temperature of normothermic rats in the anti-inflammatory dose range, but did reduce yeastinduced fever in the rat in a dose-dependent manner. Like piroxicam, meloxicam had a uricosuric effect on rats treated with oxonic acid.
Low-dose meloxicam inhibited both bradykinin-induced and PAF-induced bronchospasm in the guinea-pig, but had no effect on acetylcholine-induced bronchospasm.
Piroxicam had greater ulcerogenic effects in the rat stomach than meloxicam.
The therapeutic range of meloxicam in the rat, with regard to inhibition of adjuvant arthritis, was several times greater than that of piroxicam, indomethacin, diclofenac and naproxen.
Similar content being viewed by others
References
Vane JR. Towards a better aspirin. Nature 1994;367:215–6.
Engelhardt G. Meloxicam inhibits preferentially COX-2. Europ J Clin Pharmacol 1994;47:A98.
Engelhardt G, Bögel R, Krug I, Walcher I. Meloxicam: Lack of correlation between inhibition of PG biosynthesis in the inflammatory area and in the stomach. Magy Rheumatol 1991;32(Suppl):354.
Busch U. Pharmacokinetics of meloxicam in animals. Scand J Rheumatol 1994;(Suppl)98:A119.
Türk D, Busch U, Heinzel G, Narjes H. Basic clinical pharmacokinetic of meloxicam, a new NSAID. Scand J Rheumatol 1994;(Suppl)98:A120.
Engelhardt G, Trummlitz G. Biological activity of the main metabolites of meloxicam. Drugs Exptl Clin Res 1990;16:53–6.
Doepfner W, Cerletti A. Comparison of lysergic acid derivatives and antihistamines as inhibitors of the edema provoked in the rat's paw by serotonin. Int Archs Allergy Appl Immunol 1958;12:90–7.
Hillebrecht J. Zur routinemäßigen Prüfung antiphlogistischer Substanzen im Rattenpfotentest. Arzneim Forsch 1954;4:607–14.
Linder A. Statistische Methoden. 4th ed, Basel, Birkhäuser, 1964:148–62.
Fieller EC. A fundamental formula in the statistics of biological assay and some applications. Quart J Pharmac Pharmacol 1944;17:117–23.
Winter CHA, Risley EA, Nuss GW. Carrageenin-induced edema in hind paw of the rat as an assay for antiinflammatory drugs. Proc Soc Exper Biol Med 1962;111:544–7.
Wilhelmi G, Domenjoz R. Die Beeinflussung des Hühnereiweiß-Oedems an der Rattenpfote durch Pyrazole sowie Cortison und ACTH. Arzneim Forsch 1951;1:151–4.
Selye H. Use of “granuloma pouch” technique in the study of antiphlogistic corticoids. Proc Soc Exper Biol Med 1953;82:328–33.
Newbould BB. Chemotherapy in arthritis induced in rats by mycobacterial adjuvant. Brit J Pharmacol 1963;21:127–36.
Garland LG, Smith SJ, Sim MF. A device for the rapid measurement of rat foot volume. J Pharm Pharmacol 1968;20:236–8.
Vinegar R, Truax JF, Selph JL. Some quantitative temporal characteristics of carrageenin-induced pleurisy in the rat. Proc Soc Exp Biol Med 1973;143:711–4.
Meier R, Schuler W, Desaulles P. Zur Frage des Mechanismus der Hemmung des Bindegewebewachstums durch Cortisone. Experientia 1950;6:469–71.
Randall LO, Selitto JJ. A method for measurement of analgesic activity on inflammation tissue. Arch Int Pharmacodyn 1957;111:409–19.
Chen JYP, Beckman H. A satisfactory apparatus for study of analgesia in mice. Science 1951;113:631.
Finney DJ. Probit Analysis. 3rd ed. Cambridge: Cambridge University Press, 1971.
Haffner F. Experimentelle Prüfung schmerzstillender Mittel. Dtsch Med Wschr 1929;54:731–3.
Lembeck F, Skofitsch G. Visceral pain reflex after pretreatment with capsaicin and morphine. Naunyn-Schmied Arch Pharmakol 1982;312:116–22.
Domenjoz, R. The pharmacology of phenylbutazone analogues. Ann NY Acad Sci 1960;86:263–91.
Johnson WJ, Stavric B, Chartrand A. Uricase inhibition in the rat by s-triazines: An animal model for hyperuricemia and hyperuricosuria. Proc Soc Exp Biol Med 1969;131:8–12.
Kern A, Stransky E. Beitrag zur kolorimetrischen Bestimmung der Harnsäure. Biochem Zeitschr 1937;290:419–27.
Konzett H, Rössler R. Versuchsanordnung zu Untersuchungen an der Bronchialmuskulatur. Naunyn-Schmied Arch Pharmakol 1940;195:71–4.
Collier HOJ, Shorley PG. Analgesic antipyretic drugs as antagonists of bradykinin. Br J Pharmacol 1960;15:601–10.
Mörsdorf K, Anspach K. Zur Wirkungspontenz verschiedener Antiphlogistika bei der Carrageenin-entzündung in Vergleich zu anderen Entzündungsmodellen. Arch Int Pharmacodyn 1971; 192:111–27.
Boudinot SG, Funderburg ED, Boudinot FD. Effects of age on the pharmacokinetics of piroxicam in rats. J Pharmacol Sci 1993;82:254–7.
Ward JR, Cloud S. Comparative effect of antirheumatic drugs on adjuvant-induced polyarthritis in rats. J Pharmacol Exp Ther 1966;152:116–21.
Engelhardt G. Meloxicam: A potent inhibitor of adjuvant arthritis in the rat. Scand J Rheumatol 1994;(Suppl)98:A110.
Busch U, Engelhardt G. Distribution of [14C] meloxicam in joints of rats with adjuvant arthritis. Drugs Exptl Clin Res 1990;16:49–52.
Rivkin I, Foschi GV, Rosen CH. Inhibition of in vitro neutrophil chemotaxis and spontaneous motility by antiinflammatory agents. Proc Soc Exp Biol Med 1976;153:236–40.
Otterness IG, Larson DL, Lombardino JG. An analysis of piroxicam in rodent models of arthritis. Agents Actions 1982;12:308–12.
Fauci AS, Dale DC, Balow JE. Glucocorticoid therapy: mechanisms of action and clinical considerations. Ann Intern Med 1976;84:304–15.
Di Rosa M. Inhibition of cell migration and granuloma formation. In: Anti-inflammatory drugs. Handbook of Experimental Pharmacology. Berlin-Heidelberg-New York: Springer, 1979:50/II,223–54.
Fukuhara M, Tsurufuji S. The effect of locally injected antiinflammatory drugs on the synthesis of collagen and noncollagen protein in carrageenin granuloma in rats. Biochem Pharmacol 1969;18:2409–14.
Vane JR. Mode of action of aspirin and similar compounds. In: Robinson HJ, Vane JR, editors. Prostaglandin synthetase inhibitors. New York: Raven Press, 1974:155–64.
Malmberg AB, Yaksh TL. Hyperalgesia mediated by spinal glutamate or substance P receptor blocked by spinal cyclooxygenase inhibition. Science 1992;257:1276–9.
Swingle KF. Evaluation of antiinflammatory activity. In: Scherer RA, Whitehouse MW, editors. Antiinflammatory agents. New York-San Francisco-London: Academic Press, 1974.
Collier HOJ, Holgate JA, Schachter M, Shorley PG. An apparent bronchoconstrictor action of bradykinin and its suppression by some anti-inflammatory drugs. J Physiol 1959;149:54P–5.
Hamberg M, Svensson J, Samuelsson B. Thromboxanes: A new group of biologically active compounds derived from prostaglandin peroxides. Proc Natl Acad Sci USA 1975;72:2994–8.
Lefort J, Rotilio D, Vargaftig BB. The platelet-independent release of thromboxane A2 by PAF-acether from guinea-pig lungs involves mechanisms distinct from those for leukotrienes. Br J Pharmacol 1984;82:565–75.
Voelkel NF, Worthen S, Reeves JT, Henson PM, Murphy RC. Nonimmunological production of leukotrienes induced by platelet-activating factor. Science 1982;218:286–8.
Wynne HA, Rawlins MD. Are systemic levels of non steroidal antiinflammatory drugs relevant to an acute upper gastrointestinal haemorrhage. Eur J Clin Pharmacol 1993;44:309–13.
Kaufman DW, Kelly JP, Sheenan JE, Laszlo A. Wilholm BE, Alfredsson L, et al. Non-steroidal anti-inflammatory drug use in relation to major upper gastrointestinal bleeding. Clin Pharmacol Ther 1993;53:485–94.
Langman FJS, Weil J, Wainwright P, Lawson DH, Rawlins MD, Logan RFA, et al. Risk of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994;343:1075–8.
Djahanguiri B. The production of acute gastric ulceration by indomethacin in the rat. Scand J Gastroenterol 1969;4:265–7.
Dearden JC, Nicholson RM. Correlation between gastric irritancy and anti-inflammatory activity of non-steroidal antiinflammatory drugs. J Pharmac Pharmacol 1984;36:713–5.
Lehmann HA, Baumeister M, Lützen L, Wiegleb J. Meloxicam: A toxicology overview. Scand J Rheumatol 1995. In press.
Whittle BJR, Vane JR. A biochemical basis for the gastrointestinal toxicity of non-steroid antirheumatic drugs. Arch Toxicol 1984;7(Suppl):315–22.
Szabo S. Mechanisms of gastric mucosal injury and protection. J Clin Gastroenterol 1991;13(Suppl 2):S21–34.
Whittle BJR, Higgs GA, Eakins KE, Moncada S, Vane JR. Selective inhibition of prostaglandin production in inflammatory exudates and gastric mucosa. Nature 1980;284:271–3.
Green JR, Böttcher I, Peskar BA. Effect of a new antiinflammatory compound, CGP 28237, on arachidonate metabolism in rat gastrointestinal tissue. Agents Actions 1988;23:110–1.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Engelhardt, G., Homma, D., Schlegel, K. et al. Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance. Inflamm Res 44, 423–433 (1995). https://doi.org/10.1007/BF01757699
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01757699